AURKAIP1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3418376	1.00	1/20
Trifluoroacetic Acid (SCHEMBL3415778)	0.85	1/20
SCHEMBL3416009	0.79	1/20
SCHEMBL3411509	0.75	1/20
SCHEMBL3414676	0.74	1/20
SCHEMBL3415782	0.71	1/20
Trifluoroacetic Acid (SCHEMBL3415921)	0.70	1/20
SCHEMBL3415298	0.67	1/20
SCHEMBL3415537	0.67	1/20
Trifluoroacetic Acid (SCHEMBL3417526)	0.66	1/20
Trifluoroacetic Acid (SCHEMBL3418292)	0.66	1/20
SCHEMBL14279067	0.64	1/20
SCHEMBL3417349	0.64	1/20
SCHEMBL3417604	0.63	1/20
SCHEMBL3412666	0.62	1/20
SCHEMBL3411764	0.61	1/20
SCHEMBL3412432	0.61	1/20
SCHEMBL3416162	0.61	1/20
SCHEMBL3412325	0.60	1/20
SCHEMBL3412669	0.60	1/20

Clinical trials — most relevant to AURKAIP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder	PHASE2	WITHDRAWN
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?	PHASE1	UNKNOWN
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)	EARLY_PHASE1	COMPLETED
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Pathogenic Insights and Search for Biomarkers in RFC1-ataxia/CANVAS	nan	RECRUITING
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING
Polycystic Ovary Syndrome, Mitochondrial Dysfunction, Obesity, Insulin Resistance Infertility (POMODORI) Cohort	nan	RECRUITING
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy	nan	COMPLETED
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
The Genetics of Diabetes in Southern California Chinese Americans	nan	WITHDRAWN
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance	nan	COMPLETED
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes	nan	NOT_YET_RECRUITING
Clinical Study of Hydroxytyrosol (HT) in Mitochondrial Diseases	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine	nan	COMPLETED
Mitochondrial Dysfunction in Phelan-McDermid Syndrome	nan	COMPLETED
Skeletal Muscle Regeneration in Survivors of Critical Illness: How to Prevent Satellite Cell Failure?	nan	RECRUITING
Mitochondrial Dysfunctions Driving Insulin Resistance	nan	COMPLETED
Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence	nan	NOT_YET_RECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise	nan	COMPLETED
Insufficient Oxygenation in Septic Patients	nan	COMPLETED
Cerebrospinal Fluid Mitochondrial Biomarkers in Ischemic Stroke and Alzheimer Disease	nan	RECRUITING
GDF-15 as a Biomarker for Mitochondrial Disease	nan	COMPLETED
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a AURKAIP1 binder may also engage these)

Protein	Name	Similarity
Q9DCJ7	—	1.000	Q9DCJ7 →
Q9DCI9	—	0.975	Q9DCI9 →
Q2TBI6	—	0.975	Q2TBI6 →
Q9BYC8	—	0.974	Q9BYC8 →
P0C2B7	—	0.974	P0C2B7 →
Q99N84	—	0.974	Q99N84 →
Q9CZ83	—	0.973	Q9CZ83 →
Q0MQJ0	—	0.972	Q0MQJ0 →
MRPS18B	Small ribosomal subunit protein mS40	0.972	landscape →
Q9CQB2	—	0.972	Q9CQB2 →
Q9QXM1	—	0.971	Q9QXM1 →
Q0MQJ3	—	0.971	Q0MQJ3 →
Q0MQJ4	—	0.971	Q0MQJ4 →
Q767K8	—	0.971	Q767K8 →
NDUFB11	NADH dehydrogenase [ubiquinone] 1 beta subcom	0.971	landscape →
Q3T1H2	—	0.971	Q3T1H2 →
Q8TF30	—	0.971	Q8TF30 →
A2A9T0	—	0.971	A2A9T0 →
TERF2	Telomeric repeat-binding factor 2	0.971	landscape →
Q86XL3	—	0.971	Q86XL3 →
Q9Z136	—	0.970	Q9Z136 →
Q5TM62	—	0.970	Q5TM62 →
Q8HXG5	—	0.970	Q8HXG5 →
Q1XHY1	—	0.970	Q1XHY1 →
A3KN05	—	0.970	A3KN05 →
Q8BG80	—	0.970	Q8BG80 →
P82918	—	0.970	P82918 →
Q02225	—	0.970	Q02225 →
Q6PJ61	—	0.970	Q6PJ61 →
B1H222	—	0.970	B1H222 →